Dalbavancin

Dalbavancin is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

Dalbavancin (1500 mg single dose or 1000 mg IV on day 1 followed by 500 mg IV on day 8 to complete the course of therapy) is a long-acting lipoglycopeptide (terminal half-life of 346 hours) that inhibits cell wall biosynthesis and demonstrates concentration-dependent bactericidal activity. Dalbavancin has activity against many gram-positive aerobic bacteria, including staphylococci (including MRSA) and streptococci, and is FDA approved for acute bacterial skin and skin structure infections.

-- To view the remaining sections of this topic, please or --

General Principles

Dalbavancin (1500 mg single dose or 1000 mg IV on day 1 followed by 500 mg IV on day 8 to complete the course of therapy) is a long-acting lipoglycopeptide (terminal half-life of 346 hours) that inhibits cell wall biosynthesis and demonstrates concentration-dependent bactericidal activity. Dalbavancin has activity against many gram-positive aerobic bacteria, including staphylococci (including MRSA) and streptococci, and is FDA approved for acute bacterial skin and skin structure infections.

There's more to see -- the rest of this entry is available only to subscribers.